Serina Therapeutics Inc (SER) Stock Price, Quote & News

Company Profile

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in preclinical stage development; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214 a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which...

Industry: Biotechnology

Sector: Healthcare

Phone: 256 327 9630

Website: serinatherapeutics.com

Address:

601 Genome Way, Suite 2001, Huntsville, United States

robiein35 Dec. 4 at 4:17 AM

$SER ya CDO is still not stopping exercising and selling shares. I think unless they get positive update on IND its seems very risky.

0 · Reply

NoFearHere Dec. 4 at 2:25 AM

$SER I got an alert about it but I got to say below that trend line isn't healthy

0 · Reply

robiein35 Nov. 24 at 8:44 PM

$SER chief development officer seems to be on selling spree , he doesn’t believe in company assets looks like

0 · Reply

CometaMan Nov. 17 at 9:46 PM

$SER Good entry price, going to the market to buy pan 🥐 dulce.

0 · Reply

d_risk Nov. 13 at 1:22 PM

$SER - Serina Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors SER flags new risks of dilution and stock price pressure from $13.3M in at-the-market sales and 2025 convertible notes, plus expanded warnings on FDA approval hurdles, lack of revenue, and early-stage pipeline uncertainty. #Biotechnology #ConvertibleNotes #EarlyStagePipeline #FDAApproval #DilutionRisk 🟢 Added 🟠 Removed https://d-risk.ai/SER/10-Q/2025-11-13

0 · Reply

SorosSonosSatoshi Nov. 12 at 5:49 AM

$SER u ready for 111.111 Be feady

0 · Reply

jheerdink Nov. 6 at 12:32 AM

$SER

0 · Reply

Monogg Nov. 3 at 10:13 PM

$SER I’ve had one and a half percent of the fleet since the time when it was called Age.😁

0 · Reply

StocktwitsNews Nov. 3 at 11:36 AM

Serina Therapeutics Stock Slumps Pre-Market After FDA Places Hold On Application To Initiate Clinical Trials For Experimental Therapy $SER $VTI $VXF https://stocktwits.com/news/equity/markets/serina-therapeutics-stock-slumps-premarket-after-fda-place-hold-on-application-to-initiate-clinical-trials-for-experimental-therapy/cL2NcnCR3zB

0 · Reply

CometaMan Oct. 30 at 2:39 AM

$SER at $4.11 I am jumping in.

0 · Reply

Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of Chemistry

Dec 10, 2025, 4:30 PM EST - 3 days ago

Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program

Nov 13, 2025, 6:10 AM EST - 4 weeks ago

Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

Nov 3, 2025, 6:05 AM EST - 5 weeks ago

Serina Therapeutics Provides Regulatory Update on SER-252 Program

Oct 8, 2025, 11:00 AM EDT - 2 months ago

Serina Therapeutics Launches Enhanced Corporate Communications Platform to Strengthen Engagement with Patients, Clinicians, and Investors

Oct 6, 2025, 4:15 PM EDT - 2 months ago

Serina Therapeutics Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson's Disease

Sep 9, 2025, 3:20 PM EDT - 3 months ago

Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson's Disease

Sep 8, 2025, 6:00 AM EDT - 3 months ago

Serina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 25, 2025, 4:15 PM EDT - 3 months ago

Serina Therapeutics Announces FDA Feedback Supports Registrational Trial Design of SER-252 in Advanced Parkinson's Disease under 505(b)(2) NDA Pathway

Aug 11, 2025, 4:30 PM EDT - 4 months ago

Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

Jul 29, 2025, 6:44 AM EDT - 4 months ago

Serina Therapeutics Advances POZ-VMAT2i into Development for Tardive Dyskinesia (TD)

Jul 28, 2025, 6:00 AM EDT - 4 months ago

Serina Therapeutics to Present at the BTIG Virtual Biotechnology Conference

Jul 10, 2025, 4:10 PM EDT - 5 months ago

Serina Therapeutics Makes Grant to New Employee Under Inducement Plan

Jul 1, 2025, 4:15 PM EDT - 5 months ago

Serina Therapeutics Announces Date for 2025 Annual Stockholders Meeting

Jun 23, 2025, 7:24 PM EDT - 6 months ago

Serina Therapeutics to Present at FORCE Family Office Investor Webinar on June 26, 2025

Jun 17, 2025, 8:30 PM EDT - 6 months ago

UPDATED: Serina Therapeutics Congratulates Juvenescence Ltd. on $76M First Tranche Close of Series B Funding and Strategic Partnership with M42

Jun 17, 2025, 6:00 AM EDT - 6 months ago

Serina Therapeutics Congratulates Juvenescence Ltd. on $150M Series B Funding and Strategic Partnership with M42

Jun 9, 2025, 4:05 PM EDT - 6 months ago

Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event "Is the Beaten Down Biotech Sector the Smartest Bet in Today's Volatile Market?"

May 22, 2025, 4:50 PM EDT - 7 months ago

Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors

May 14, 2025, 3:15 PM EDT - 7 months ago

Serina Therapeutics Makes Grants to New Employees Under Inducement Plan

May 8, 2025, 4:23 PM EDT - 7 months ago

Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

Apr 29, 2025, 6:00 AM EDT - 8 months ago

Serina Therapeutics to Present at JonesResearch Virtual CNS Day

Apr 15, 2025, 6:30 AM EDT - 8 months ago

Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit

Apr 8, 2025, 4:30 PM EDT - 8 months ago

Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson's Disease

Apr 7, 2025, 6:30 AM EDT - 8 months ago

Serina Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference

Mar 24, 2025, 4:30 PM EDT - 9 months ago

Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

Mar 24, 2025, 6:30 AM EDT - 9 months ago

Serina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 Meeting

Feb 12, 2025, 4:15 PM EST - 10 months ago

Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors

Feb 3, 2025, 4:30 PM EST - 11 months ago

Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients

Jan 15, 2025, 4:05 PM EST - 11 months ago

Serina Therapeutics Announces Sale of UniverXome Subsidiary

Jan 14, 2025, 5:25 PM EST - 11 months ago

Serina Therapeutics Welcomes Karen J. Wilson to its Board of Directors

Dec 16, 2024, 6:00 AM EST - 1 year ago

Serina Therapeutics to Present at Tribe Public's Webinar Event "Enabling Continuous Drug Delivery for Parkinson's Disease & Beyond" on Wednesday, December 18, 2024

Dec 11, 2024, 6:05 AM EST - 1 year ago

Serina Therapeutics to Present at the 3rd Annual LNP Immunogenicity & Toxicity Summit

Dec 2, 2024, 5:22 PM EST - 1 year ago

Serina Therapeutics Secures $10 Million Financing to Continue Advancing Lead IND Candidate into Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients

Nov 12, 2024, 5:00 PM EST - 1 year ago

Serina Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Sep 4, 2024, 6:42 PM EDT - 1 year ago

Serina Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 9, 2024, 4:15 PM EDT - 1 year ago

Serina Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights

Jul 29, 2024, 8:30 AM EDT - 1 year ago

Serina Therapeutics to Present Novel Data on POZ-Lipid Technology Potentially Enhancing Safety and Efficacy of mRNA LNP Formulations at the 4th mRNA-Based Therapeutics Summit

Jul 18, 2024, 5:00 PM EDT - 1 year ago

Serina Therapeutics Appoints Srini Tenjarla, Ph.D. as Senior Vice President of CMC and Formulation

May 14, 2024, 4:05 PM EDT - 1 year ago

Serina Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights

Apr 17, 2024, 4:05 PM EDT - 1 year ago

Serina Therapeutics Appoints Dr. Simba Gill as Executive Chairman

Mar 26, 2024, 5:04 PM EDT - 1 year ago

Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics

Mar 22, 2024, 5:27 PM EDT - 1 year ago

AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results

Feb 27, 2024, 3:19 PM EST - 1 year ago

AGEX THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AgeX Therapeutics, Inc. - AGE

Nov 14, 2023, 4:05 PM EST - 2 years ago

AgeX Therapeutics Reports Third Quarter 2023 Financial Results

Aug 30, 2023, 7:00 AM EDT - 2 years ago

Serina Therapeutics and AgeX Therapeutics Enter into Merger Agreement

Aug 14, 2023, 4:05 PM EDT - 2 years ago

AgeX Therapeutics Reports Second Quarter 2023 Financial Results

Jul 24, 2023, 6:28 PM EDT - 2 years ago

AgeX Therapeutics Closes $36,000,000 Debt Exchange for Preferred Stock

robiein35 Dec. 4 at 4:17 AM

$SER ya CDO is still not stopping exercising and selling shares. I think unless they get positive update on IND its seems very risky.

0 · Reply

NoFearHere Dec. 4 at 2:25 AM

$SER I got an alert about it but I got to say below that trend line isn't healthy

0 · Reply

robiein35 Nov. 24 at 8:44 PM

$SER chief development officer seems to be on selling spree , he doesn’t believe in company assets looks like

0 · Reply

CometaMan Nov. 17 at 9:46 PM

$SER Good entry price, going to the market to buy pan 🥐 dulce.

0 · Reply

d_risk Nov. 13 at 1:22 PM

0 · Reply

SorosSonosSatoshi Nov. 12 at 5:49 AM

$SER u ready for 111.111 Be feady

0 · Reply

jheerdink Nov. 6 at 12:32 AM

$SER

0 · Reply

Monogg Nov. 3 at 10:13 PM

$SER I’ve had one and a half percent of the fleet since the time when it was called Age.😁

0 · Reply

StocktwitsNews Nov. 3 at 11:36 AM

0 · Reply

CometaMan Oct. 30 at 2:39 AM

$SER at $4.11 I am jumping in.

0 · Reply

CometaMan Oct. 30 at 2:37 AM

$SER why the cheap price?

0 · Reply

titto25 Oct. 24 at 3:52 PM

$SER eventually will see 10 imo

0 · Reply

Tonyda Oct. 13 at 8:38 PM

$RR $SER $SYM Luke, fry and Louis is saying physical ai is the next biggest wave - 21 trillion dollar industry bigger than digital ai

0 · Reply

Tonyda Oct. 13 at 8:26 PM

$RR $SER $SYM give more humanoid robotic stocks trending up

0 · Reply

StockElementCorporation Oct. 13 at 8:06 PM

Really good theme to get into is robotics . If an opportunity presents itself ; we’ll jump on it. $SER $RR $SYM

0 · Reply

PremarketAnalysis Oct. 8 at 4:39 PM

$SER fading after push near 5.7 with sellers regaining short control.. algo flow light and BRX 20 range.. watching 5.4 to 5.5 zone for next move setup. Momentum Feed: https://premarketanalysis.com/#momentum=SER

0 · Reply

jheerdink Oct. 7 at 3:00 PM

$SER https://vistapglobal.com/investing-in-biotechs-next-wave-serina-therapeutics-blends-vision-and-scientific-rigor-ser-bhvn-ibb-xbi/

0 · Reply

ChartChartist Oct. 7 at 12:08 AM

$SER on promo, ww

2 · Reply

titto25 Oct. 1 at 10:37 AM

$SER 7 imo

0 · Reply

titto25 Sep. 12 at 7:26 PM

$SER worth much more maybe 7 or 8 imo

0 · Reply

NVDAMillionaire Sep. 11 at 6:12 AM

$SER Excellent article that nails exactly where SER stands right now. So if you want to update your SER knowledge or get acquainted with SER, this is a must read. https://beyondspx.com/quote/SER/analysis/serina-therapeutics-unlocking-neurological-potential-with-poz-despite-liquidity-headwinds-nyse-american-ser

0 · Reply

jheerdink Sep. 10 at 1:38 PM

$SER Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced that it has entered into an agreement to access up to $20 million in financing led by Serina Board Director Greg Bailey, MD. The financing also includes the issuance of warrants which, if fully issued and exercised, could result in additional proceeds of up to $20 million. https://finance.yahoo.com/news/serina-therapeutics-secures-20-million-192000794.html

0 · Reply

Market Cap	33.27M
Revenue (ttm)	60,000.00
Net Income (ttm)	-11.14M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-18,566.67%
Debt to Equity Ratio	0.00

Volume	13,100
Avg Vol	28,338
Day's Range	N/A - N/A
Shares Out	10.66M
Stochastic %K	0%
Beta	1.06
Analysts	Strong Sell
Price Target	$13.00